Galectin Therapeutics (GALT) Non-Current Assets (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Non-Current Assets came in at $68000.0 in Q1 2026, down 72.02% year-on-year from $243000.0 in Q1 2025, and down 29.17% quarter-over-quarter from $96000.0 in Q4 2025.
Galectin Therapeutics (GALT) Non-Current Assets (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $68000.0 for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 72.02% year-over-year to $68000.0 in Q1 2026; TTM through Mar 2026 was $475000.0, a 59.05% decrease from a year earlier, with the FY2025 full-year figure at $96000.0, down 60.49% from the prior year.
- Non-Current Assets declined to $68000.0 in Q1 2026 per GALT's latest filing, from $96000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $793000.0 in Q3 2022 and bottomed at $68000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $306000.0 (2024), against an average of $360470.6.
- Across the five-year window, Non-Current Assets soared 10371.43% in 2022 and sank 72.02% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $733000.0 in 2022, then tumbled by 33.15% to $490000.0 in 2023, then tumbled by 50.41% to $243000.0 in 2024, then tumbled by 60.49% to $96000.0 in 2025, then fell by 29.17% to $68000.0 in 2026.
- Per Business Quant, the three latest GALT Non-Current Assets figures stand at $68000.0 (Q1 2026), $96000.0 (Q4 2025), and $136000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 96,000.00 |
| Sep 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 175,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 490,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 613,000.00 |
| Mar 31, 2023 | 673,000.00 |
| Dec 31, 2022 | 733,000.00 |
| Sep 30, 2022 | 793,000.00 |
| Jun 30, 2022 | 101,000.00 |
| Mar 31, 2022 | 108,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 71,000.00 |